---
title: About Us | Propria LLC
---

# News and Publications

 

Propria’s engineered heart tissue technology has contributed substantially to scientific presentations and peer-reviewed publications in recent years.

November 2025

# [Discovery of small molecule modulators of the thin filament that alter the contractile profile in a hypertrophic cardiomyopathy engineered tissue model](https://www.jbc.org/article/S0021-9258(25)02790-5/fulltext)

July 2025

# [Preclinical Characterization of CK-4021586, a new class of cardiac myosin inhibitors, for the treatment of heart failure with preserved ejection fraction](https://aha.abstractarchives.com/abstract/bcvs2025-4309618/preclinical-characterization-of-ck-4021586-a-new-class-of-cardiac-myosin-inhibitors-for-the-treatment-of-heart-failure-with-preserved-ejection-fraction)

July 2025

# [Evaluating pathogenicity of TPM1 variants of unknown significance using in-silico and in-vitro models](https://www.sciencedirect.com/science/article/pii/S3050632825000083)

October 2024

# [Distinct mechanisms drive divergent phenotypes in hypertrophic and dilated cardiomyopathy-associated TPM1 variants  ](https://www.jci.org/articles/view/179135)

August 2024

# [In silico and in vitro models reveal the molecular mechanisms of hypocontractility caused by TPM1 M8R](https://pubmed.ncbi.nlm.nih.gov/39282088/)

May 2024

# [A transcriptional enhancer regulates cardiac maturation ](https://www.nature.com/articles/s44161-024-00484-2)

January 2024

# [Classifying pathogenicity of TPM1 variants of unknown significance using in vitro and in silico approaches](https://www.sciencedirect.com/science/article/abs/pii/S1071916423008540?casa_token=ZdTtRJpSHykAAAAA:ODhNd_-zHB8Jb-GAsD55KtIZUZoQVhhGEfJIP8dWWZ1S9iT4oSlUmQHmwUncjetbTUcyMLwIJA)

January 2024

# [Cardiac Localized Polycystin-2 plays a Functional Role in Natriuretic Peptide Production and its Absence Contributes to Hypertension](https://www.biorxiv.org/content/10.1101/2024.01.02.573922v1.full)

November 2023

# [Abstract 17931: Auxotonic MyoPod® Engineered Heart Tissues Enable Longitudinal Tracking of in vitro Development of Hypertrophic Cardiomyopathy](https://www.ahajournals.org/doi/abs/10.1161/circ.148.suppl_1.17931)

November 2023

# [American Heart Association Scientific Sessions -Rapid Fire Oral: EDG-7500, a Cardiac Sarcomere Regulator That Preserves Intrinsic Myosin-Motor Function, Improves Cardiac Function and Reserve in a Minipig Model of Hypertrophic Cardiomyopathy](https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.15612)

November 2023

# [American Heart Association Scientific Sessions - Poster: Acute Treatment With Aficamten Rescues Contractile Function in a MyoPod® Engineered Heart Tissue Model of Hypertrophic Cardiomyopathy](https://cytokinetics.com/wp-content/uploads/2023/11/AHA-SS-2023_Propria-Cytokinetics-Poster_FINAL.pdf)

October 2023

# [Chronic diastolic stretch unmasks conduction defects in an in vitro model of arrhythmogenic cardiomyopathy](https://pubmed.ncbi.nlm.nih.gov/37830983/)

October 2023

# [Evaluation of Porcine Psoas Major as a Scaffold Material for Engineered Heart Tissues](https://www.liebertpub.com/doi/abs/10.1089/ten.TEC.2023.0064)

March 2023

# [Increased length-dependent activation of human engineered heart tissue after chronic α1A-adrenergic agonist treatment: testing a novel heart failure therapy](https://journals.physiology.org/doi/full/10.1152/ajpheart.00279.2022)

February 2023

# [Modeling Hypertrophic Cardiomyopathy Due to MYBPC3 Haploinsufficiency with Engineered Heart Tissues](https://www.tenayatherapeutics.com/wp-content/uploads/2023-Keystone-Poster-MYBCP3.pdf)

January 2023

# [Mechanisms of pathogenicity in the hypertrophic cardiomyopathy-associated TPM1 variant S215L](https://pubmed.ncbi.nlm.nih.gov/36896133/#:~:text=These%20data%20form%20a%20mechanistic,induction%20of%20a%20hypertrophic%20phenotype.)

November 2022

# [Abstract P1056: Stretch Reduces Inter-filament Spacing And Triggers Alterations In Thick-filament Structure In Healthy Left-atrial Fibers](https://www.ahajournals.org/doi/abs/10.1161/res.131.suppl_1.P1056)

September 2022

# [Physiological calcium combined with electrical pacing accelerates maturation of human engineered heart tissue](https://pubmed.ncbi.nlm.nih.gov/35931080/)

April 2022

# [Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy](https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056265)

March 2022

# [GSK-3β Localizes to the Cardiac Z-Disc to Maintain Length Dependent Activation](https://pubmed.ncbi.nlm.nih.gov/35168370/)

May 2022

# [Multiscale Modeling of Familial Cardiomyopathy-linked Tropomyosin Mutations](https://elischolar.library.yale.edu/cgi/viewcontent.cgi?article=1577&context=gsas_dissertations)

November 2021

# [Abstract 14185: Acute Pacing Regimen Strengthens Engineered Human Cardiac Tissue](https://www.ahajournals.org/doi/abs/10.1161/circ.144.suppl_1.14185)

## Request Information

### If you have any questions or would like more information about Propria, please fill out the form below.